Relay Therapeutics, Inc. Hits New 52-Week High of $11.43

Relay Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 11.43 on February 27, 2026. This achievement marks a notable increase from its 52-week low of USD 1.78, showcasing a remarkable performance over the past year. The stock has demonstrated a robust annual growth rate of 36.25%, significantly outperforming the S&P 500, which recorded a gain of 17.36% during the same period. As a small-cap company in the Pharmaceuticals & Biotechnology sector, Relay Therapeutics holds a market capitalization of USD 1,508 million. Despite being in a loss-making position, the company continues to attract attention within its industry. Key financial metrics include a price-to-book ratio of 2.48 and a debt-to-equity ratio of -0.98, indicating a unique financial structure. The company does not currently offer a dividend yield, reflecting its focus on growth and reinvestment. This recent price movement underscores Relay Therapeutics' evolving market position and performance within the competitive landscape of biotechnology.